3MM Stock Chart & Stats
€1.67
€0.03(1.75%)
At close: 4:00 PM EST
€1.67
€0.03(1.75%)
Day’s Range― - ―
52-Week Range€0.81 - €2.20
Previous CloseN/A
Volume0.00
Average Volume (3M)53.00
Market Cap
€23.99M
Enterprise Value€42.82
Total Cash (Recent Filing)€1.34M
Total Debt (Recent Filing)€19.00M
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Sep 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding14,609,619
10 Day Avg. Volume61
30 Day Avg. Volume53
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-0.87
Price to Sales (P/S)3.81
P/FCF Ratio-5.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.47
Revenue Forecast (FY)€6.60M
Bulls Say, Bears Say
Bulls Say
Niche Specialty ProductAdvicenne sells a proprietary prolonged‑release formulation (Sibnayal) for rare renal disorders, a narrow specialist indication. Chronic treatment needs and few direct competitors in rare dRTA niches create a durable, predictable prescription base and pricing leverage over time.
Improving Gross ProfitabilityThe shift to positive gross margins in 2025 signals improving product economics and potential scale benefits on cost of goods sold. If sustained alongside controlled SG&A, stronger gross profitability materially improves the path to operating leverage and longer‑term viability.
Recurring Prescription Revenue ModelA prescription‑based revenue model for chronic rare diseases supports recurring revenue if patient diagnosis, adherence and reimbursement hold. The model also allows for licensing or distribution deals, giving multiple channels to scale sales without proportional fixed cost increases.
Bears Say
Negative Equity / Fragile Capital StructureSustained negative equity reflects accumulated losses that materially weaken the balance sheet. This restricts borrowing capacity, increases financing risk and potential dilution, and limits the company’s ability to fund commercialization or R&D initiatives from internal resources over the medium term.
Persistent Cash BurnRepeated negative operating and free cash flow means the business depends on external funding to sustain operations and commercial rollout. Intermittent improvements were not sustained in 2025, leaving a durable financing need that can constrain strategy or force dilutive capital raises.
Small, Volatile Revenue And Recurring LossesVolatile and small revenue with recurring operating losses undermines visibility into commercial traction and scale economics. Negative 2025 growth demonstrates fragility in demand or market access, making sustained margin improvement and self‑funded growth uncertain without strategic execution or additional resources.
Advicenne SA News
3MM FAQ
What was Advicenne SA’s price range in the past 12 months?
Advicenne SA lowest stock price was €0.81 and its highest was €2.20 in the past 12 months.
What is Advicenne SA’s market cap?
Advicenne SA’s market cap is €23.99M.
When is Advicenne SA’s upcoming earnings report date?
Advicenne SA’s upcoming earnings report date is Sep 17, 2026 which is in 50 days.
How were Advicenne SA’s earnings last quarter?
Advicenne SA released its earnings results on Mar 26, 2026. The company reported -€0.314 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Advicenne SA overvalued?
According to Wall Street analysts Advicenne SA’s price is currently Overvalued.
Does Advicenne SA pay dividends?
Advicenne SA does not currently pay dividends.
What is Advicenne SA’s EPS estimate?
Advicenne SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Advicenne SA have?
Advicenne SA has 14,609,619 shares outstanding.
What happened to Advicenne SA’s price movement after its last earnings report?
Advicenne SA reported an EPS of -€0.314 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 15.881%.
Which hedge fund is a major shareholder of Advicenne SA?
Currently, no hedge funds are holding shares in DE:3MM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Advicenne SA
Advicenne S.A. operates as a specialized pharmaceutical firm, focusing on the innovation and commercialization of therapeutic solutions for various kidney-related disorders. The company's primary offering, Sibnayal, targets both distal renal tubular acidosis and cystinuria. Established in 2007, Advicenne S.A. maintains its principal offices in Paris, France.